Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1756287215574457 http://scihub22266oqcxt.onion/10.1177/1756287215574457 C4485412!4485412!26161146     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Adv+Urol 2015 ; 7 (3): 152-61 Nephropedia Template TP {{tp|p=26161146|t=2015. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma |pdf=|usr=}}{{26161146}} gab.com Text Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma JO: Ther Adv Urol http://www.kidney.de/pget.php?&tw=1&pmid=26161146 #FOAvip Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as the first-line treatment indicated in mRCC patients classified as poor risk. The benefits of temsirolimus are not limited to an increased survival but are also related to a better quality of life, which is certainly one of the most important aspects in the clinical management of these frail patients. Temsirolimus is a well-tolerated treatment, and the most frequent adverse events are manageable with supportive care. To this end, the identification of predictive factors of response to temsirolimus could help us to better select patients and obtain a more tailored clinical management of mRCC. Twit Text FOAVip Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma ????Ther Adv Urol http://www.kidney.de/pget.php?&tw=1&pmid=26161146 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26161146 #FOAvip English Wikipedia <ref>{{Cite pmid|26161146}}</ref> Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma #MMPMID26161146 Zanardi E; Verzoni E; Grassi P; Necchi A; Giannatempo P; Raggi D; De Braud F; Procopio G Ther Adv Urol 2015[Jun]; 7 (3): 152-61 PMID26161146show ga Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as the first-line treatment indicated in mRCC patients classified as poor risk. The benefits of temsirolimus are not limited to an increased survival but are also related to a better quality of life, which is certainly one of the most important aspects in the clinical management of these frail patients. Temsirolimus is a well-tolerated treatment, and the most frequent adverse events are manageable with supportive care. To this end, the identification of predictive factors of response to temsirolimus could help us to better select patients and obtain a more tailored clinical management of mRCC. äClinical experience with temsirolimus in the treatment of advanced ren(epmc).pdf DeepDyve Pubget Overpricing